iiinova — where your digital self keeps evolving

Reposted by Sandip Patel, MD FASCO

Lung Cancer Research Foundation @lcrf.org · 26/04/2026

Join us for a special Together Separately community livestream presented by The Susan Wojcicki Foundation! DNA: A Blueprint for Lung Cancer Research will be held Thur, May 14, 1:30pm ET. SIgn up: LCRF.org/together @pateloncology.bsky.social @jfreemandaily.bsky.social @go2forlungcancer.bsky.social

041

Sandip Patel, MD FASCO @pateloncology.bsky.social · 02/10/2025

Thanks @ASCO #ASCODailyNews for sharing our work on “What Is the Role of Machine Learning in Oncology Today?” led by @UCSDCancer fellow @TaliAzen dailynews.ascopubs.org/do/role-mach...

050

Sandip Patel, MD FASCO @pateloncology.bsky.social · 27/05/2025

Looking forward to @asco later this week! Avoid the traffic when heading to the loop and take a shuttle or the Metra train which runs from inside McCormick to Millennium station. @ConquerCancerFd kindly sponsors a free digital Metra ticket

060

Sandip Patel, MD FASCO @pateloncology.bsky.social · 22/05/2025

Looking forward to a great @ASCO Educational Session on utilizing artificial intelligence to accelerated oncology clinical trials with perspectives from FDA and FNIH on 5/30 430pm CST in S102, please join us for this pan-institutional discussion

040

Sandip Patel, MD FASCO @pateloncology.bsky.social · 21/05/2025

Please join @DrAlexAdjei #DrRebeccaHeist and myself @ASCO on 5/30 630p CST at Sheraton Grand Chicago Riverwalk for a great discussion around MET targeted in NSCLC @gotoPER

041

Sandip Patel, MD FASCO @pateloncology.bsky.social · 14/05/2025

Great to have new protein targeting ADCs (teliso-V for high MET in refractory NSCLC most recently), but one issue is we lack of liquid biopsy or multiplex platform for all the IHc targets we need (HER2, MET, PD-L1) and likely others upcoming. Multiplex/dig path solutions here.

021

Reposted by Sandip Patel, MD FASCO

Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 29/04/2025

Tuesday at #AACR25 looks to be action-packed with reports of progress on cell therapy in solid tumors! @pateloncology.bsky.social

041

Sandip Patel, MD FASCO @pateloncology.bsky.social · 24/04/2025

Looking to be an outstanding @theaacr.bsky.social Clinical Trials Plenary session on Bispecifics and T cell engagers on Tues 4/29 10:15am CST featuring #wolchokj #hoperugo #jasonlukemd and other outstanding faculty. I am excited to be discussing CART in thyroid cancer in this great program

061

Sandip Patel, MD FASCO @pateloncology.bsky.social · 28/03/2025

Thanks to @ASCO! I am grateful for this honor with these outstanding faculty and organization and look forward to seeing everyone in a few months in Chicago

080

Sandip Patel, MD FASCO @pateloncology.bsky.social · 10/03/2025

Attention #OncologyFellows! Submit your #LungCancer essay by March 28 for a chance to join us in Chicago at #ASCO2025! This is an incredible opportunity to broaden your network, and gain invaluable experience. Don’t miss out—submit your essay www.surveymonkey.com/r/PS58XJ6 🚀

020

Reposted by Sandip Patel, MD FASCO

Narjust Florez, MD, FASCO @narjustflorezmd.bsky.social · 26/01/2025

Great opportunity to share the stage with colleagues that have become friends at STS @pateloncology.bsky.social

071

Reposted by Sandip Patel, MD FASCO

PeerView @peerview.bsky.social · 15/01/2025

🎥✨ Hear from @pateloncology.bsky.social as he shares a preview of our upcoming PeerView symposium at #STS2025! Join us in LA on 1/25 for expert discussions, interactive sessions, and cutting-edge insights. Don’t miss it—watch the teaser now! 👉 bit.ly/Immuno-LA-T #MedEd #Medsky #Oncsky

0145

Reposted by Sandip Patel, MD FASCO

Daniel Stover, MD, FASCO @stoverlab.bsky.social · 30/11/2024

Do systemic responses to ICI (eg irAEs) associate w outcomes? Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al

1268

Reposted by Sandip Patel, MD FASCO

Gregory Riely @rielymd.bsky.social · 15/11/2024

@pateloncology.bsky.social on his approach to immunotherapy in patients with NSCLC

0101